Cabinet Committee on Economic Affairs, CCEA today cleared private equity major KKR's proposals to acquire stakes in two pharmaceutical companies. Highly placed sources said, the two deals are estimated to be worth 1,434 crore rupees. The first proposal relates to acquisition of about 38 per cent stake by KKR Floorline Investments PTE in Hyderabad-based Gland Pharma.In the other proposal cleared by the CCEA, KKR would acquire 24.9 per cent stake in Gland Celsus Bio Chemicals Pvt Ltd. In January this year, Competition Commission of India had approved the deals.The CCEA also ratified the decision to sell 4.66 percent stake in power equipment maker BHEL through block deal route. Finance Ministry in March had sold 4.66 per cent stake in the state-owned company to Life Insurance Corporation (LIC) for about 1,889 crore rupees. LIC purchased 11.41 crore shares in BHEL at a price of 165.55 rupees a piece through a block deal on the BSE.Following the block deal, government stake in BHEL came down to 63.06 per cent, from 67.72 per cent. The Empowered Group of Ministers, headed by Finance Minister P Chidambaram, had in February, decided on the timing and mode of disinvestments in BHEL. However, the CCEA approval was pending for the stake sale.